On July 9, 2017, the three-year term of Gil Oren, an external director of Can-Fite Biopharma Ltd. and member of the audit committee and compensation committee of the company, automatically expired. Mr. Oren may not be re-elected to serve as an external director for an additional term as he was elected for the maximum number of terms permitted under the Israeli Companies Law. As previously reported, on July 25, 2017, the company plans to hold its 2017 Annual General Meeting of shareholders, at which meeting, among other things, Yaacov Goldman, is standing for election to replace Mr. Oren as an external director and as a member of the company’s audit committee and compensation committee.